The cell banking outsourcing market size is estimated to be USD 9,911.3 million in 2022 and is expected to witness a CAGR of 16.54% during the forecast period 2023-2033. The rising advancements of cryopreservation and cell bank preparation techniques, surging use of stem cell therapies, growing adoption for monoclonal antibodies, and efficient biopharmaceuticals. are factors contributing to the market growth. Furthermore, collaboration of key competitors and expanding older population is projected to propel the market growth. However, lack of knowledge about stem cell preservation, ethical concerns, and the increasing cost of cell banking in some developing nations is expected to hinder the growth.

Expanding older population is expected to spur the market. It is predicted that rising biopharmaceutical manufacturing and rising demand for stem cell therapy will drive the expansion of the worldwide cell banking outsourcing market. The demand for stem cell therapy among the elderly population worldwide is fairly high. Therefore, the expanding elderly population worldwide is also anticipated to have a significant impact on the market’s expansion. The number and percentage of the geriatric population—those adults 60 years of age and older—in the population is growing, according to data from the World Health Organization (WHO).There were 1 billion older people worldwide in 2019. This number is anticipated to increase to 1.4 billion by 2030 and to 2.1 billion by 2050.

The key competitors in the market are collaborating together on research projects to convert newborn stem cells from umbilical cord blood and tissue into iPSCs. Over the course of the projection period, these collaborations are also anticipated to fuel market expansion. For instance, Opsis Therapeutics, FUJIFILM Cellular Dynamics, and Blue Rock Therapeutics collaborated on strategic research and development to develop cell treatments for the treatment of eye diseases in May 2021. These companies will apply their knowledge to create pre-made iPSCs that can treat eye diseases.

Segmentation

By Type

The market is categorized into working cell banking, master cell banking, and viral cell banking. In 2022, the master cell banking accounted for the highest revenue share due to the fact that it is essential for the development and use of functional cell banks. They are preserved for a substantially longer period of time, which also encourages the use of high-grade cryopreservation techniques and tools, thus boosting the segment’s revenue base. Additionally, master cell banks are beneficial in a wide range of research and development areas related to gene and stem cell therapies. A major factor anticipated to drive the growth of this market during the forecast period is the rise in autoimmune diseases and cancer cases that can be treated with medicines combined with regenerative medicine.

By Cell Type

The market is categorized into non-stem cell and stem cell. In the global market, the stem cell segment accounted for the largest revenue share in 2022 owing to rise in research and development efforts related to stem cell applications. In contrast to somatic cells that have been retained for uses like tissue engineering and IPS cell development, stem cells can be extracted from cord blood, embryonic, adult, dental, and IPS cells. The expansion of this market sector is driven by an increase in research and development projects related to stem cell applications. For instance, American CryoStem and BioTherapeutic Labs Corp. worked together in February 2021 to advance stem cell research and development.

By Phase

The market is segmented into bank characterization & testing, bank preparation and bank storage. In 2022, the bank storage segment accounted for the largest revenue share owing to advanced preservation requirements that are required for the appropriate maintenance of either master or operational banks. Cryopreservation methods with the newest technology are also anticipated to propel this market’s expansion throughout the course of the projected year. For instance, Creative Biogene provides its clients with a comprehensive bank characterization service to ensure the biosafety and management of biotechnological and biological products. Bank characterization is projected to contribute to the lucrative expansion of the industry during the forecast period due to the presence of market players engaged in offering outsourcing services for bank characterization.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cell banking outsourcing market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of several R&D facilities and the rising prevalence of metabolic disorders including Parkinson’s, Alzheimer’s, and various other forms of cancers. The organisational diversity in the healthcare system of North America is also driven by the rapid growth in the formation of financial services, an indication of rapid change. Asia Pacific is anticipated to increase significantly during the predicted period. Pharmaceutical firms, which are concentrating their efforts on the sizable and largely untapped populations in Asia, are to responsible for this exponential CAGR. Strong investments in the biotechnology sector and low cost of clinical trials are anticipated to drive this region’s market expansion. Aiming to provide academics, researchers, and industry experts with a forum to present their work and discuss breakthroughs and advancements in stem cell, the International Conference on Stem Cell Research and Therapy was held in China in May 2022. It is projected that discussions and support for stem cell research by corporate and public groups will contribute to the expansion of this sector.

Competitor Insights

Some of the key players operating in the cell banking outsourcing market are Goodwin Biotechnology Inc., BioReliance, BioOutsource (Sartorious), Covance, Cryo-Cell International, Inc, BSL Bioservice, Charles River Laboratories, Global Stem Inc., Lonza, and SGS Life Sciences.

To increase their market position, key companies in this market are implementing several strategies into practise, such as alliances formed through mergers and acquisitions, geographic expansion, and strategic collaborations.

• For instance, Duke University and Cryo-Cell International, Inc., the first private cord blood bank in the world, agreed into a collaborative licence deal in February 2021. The business aims to grow its key business segments through this agreement.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type, cell type, and phase from 2023 to 2033.

Report Scope:

Segmentation: Cell Banking Outsourcing Market Report 2022 – 2033

Type (Revenue, USD Million), 2022 – 2033

• Working Cell Banking
• Master Cell Banking
• Viral Cell Banking

Cell Type (Revenue, USD Million), 2022 – 2033

• Non-stem Cell
• Stem Cell
  • Embryonic Stem Cell Banking
  • IPS Stem Cell Banking
  • Cord Cell Banking
  • Adult Stem Cell Banking
  • Dental Stem Cell Banking

Phase (Revenue, USD Million), 2022 – 2033

• Bank Characterization & Testing
  • Karyology Testing
  • Safety Testing
  • Gene Sequencing Testing
  • Gene Expression Testing
• Bank Preparation
  • Working Cell Bank Preparation
  • Master Cell Bank Preparation
• Bank Storage
  • Working Cell Bank Storage
  • Cell Storage Stability Testing
  • Master Cell Bank Storage

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA